Biovica is uniquely positioned to address one of the major challenges in cancer therapy today; how to better evaluate therapeutic efficacy and improve quality of life in patients with advanced stages of the disease.
A simple blood sample
DiviTum® is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. It offers several advantages over alternative techniques that are standard in advanced breast cancer. In several clinical trials, the DiviTum® biomarker assay has demonstrated the potential to quickly evaluate treatment effect and accurately predict outcome using just a simple blood sample.
New unique data from US breast cancer congress
The results demonstrate that palbociclib significantly reduced serum TK-activity levels in patients with hormone sensitive, HER2- breast cancer already after 2 weeks of treatment. DiviTum® measured changes in serum TK-activity that was significantly correlated to the tumor Ki67 proliferation index. DiviTum® may thus serve as a non-invasive marker and early response indicator of the anti-proliferative effect of CDK4/6 inhibitors like palbociclib.
Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.
Clinical Cancer Research publishes results supporting DiviTum as a technology for early evaluation of metastatic breast cancer treatment
Biovica, active in cancer diagnostics, today announced that the scientific journal Clinical Cancer Research has published data from the TREnd study, demonstrating the benefits of using DiviTum[®] when evaluating palbociclib treatment outcome in women with metastatic breast cancer.
Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.
“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world's largest scientific conference on breast cancer”. - Anders Rylander, CEO of Biovica
BEST POSSIBLE TREATMENT FROM DAY ONE
Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum® biomarker assay, aim to increase survival and improve quality of life.
Clinical trials and Collaborations
Biovica has successfully worked to realize its vision for Divitum® by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).